These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7998088)

  • 1. Severe allograft dysfunction after OKT3-induced human herpes virus-6 reactivation.
    Jacobs U; Ferber J; Klehr HU
    Transplant Proc; 1994 Dec; 26(6):3121. PubMed ID: 7998088
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
    Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
    Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA.
    Lloveras J; Puig JM; Oliveras A; Orfila A; Comerma I; Aubia J; Masramón J
    Transplant Proc; 1992 Feb; 24(1):43-4. PubMed ID: 1539335
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytokine-release syndrome: differences between high and low doses of OKT3.
    Norman DJ; Kimball JA; Barry JM
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
    Alamartine E; Bellakoul R; Berthoux F
    Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 10. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results.
    Pomer S; Waldherr R; Möhring K; Kempter F; Wiesel M; Weimer R
    Transplant Proc; 1992 Oct; 24(5):1732-3. PubMed ID: 1412815
    [No Abstract]   [Full Text] [Related]  

  • 14. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of cyclosporine rescue therapy in steroid resistant rejections.
    Sharma RK; Elhence R; Kher V; Gupta A; Kumar A; Bhandari M; Agrawal S
    Transplant Proc; 1994 Oct; 26(5):2556-7. PubMed ID: 7940789
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular effects of ATG and OKT3 in renal allograft recipients.
    Spieker C; Barenbrock M; Buchholz B; Heidenreich S; Zidek W
    Transplant Proc; 1992 Dec; 24(6):2594-5. PubMed ID: 1465876
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequential monitoring of immunoregulatory T cell subsets in renal transplantation.
    Mestre M; González C; Griño JM; Valls A; Bonete J; Mané E; Corominas M; Bas J; Romeu A; Buendia E
    Transplant Proc; 1992 Feb; 24(1):73-5. PubMed ID: 1539351
    [No Abstract]   [Full Text] [Related]  

  • 19. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

  • 20. ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial.
    Stippel DL; Arns W; Pollok M; Beckurts KT; Hesse UJ; Hölscher AH
    Transplant Proc; 2002 Sep; 34(6):2201-2. PubMed ID: 12270362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.